Adamas Pharma (ADMS) Misses Q2 EPS by 12c

Adamas Pharma (NASDAQ: ADMS) reported Q2 EPS of ($0.93), $0.12 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $0 versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15